Compare Boston Scientific Corporation (BSX) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Honeywell International Inc — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while Honeywell International Inc trades at $230.07 (market cap $76.99B). The key difference: Boston Scientific Corporation and Honeywell International Inc are close in size by market cap, and Honeywell International Inc pays a 1.15% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | HON | |
|---|---|---|
Market Cap | $71.46B | $76.99B |
Sector | Health | Industrials |
52-Week High | $108.14 | $248.79 |
52-Week Low | $42.63 | $188.14 |
Enterprise Value | $83.55B | $101.79B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
Honeywell Technologies (HON) trades at $246.19, up 2.26% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company has completed strategic divestitures to focus on automation. Key financials show a P/E of 9.47, net income margin of 21.58%, and robust cash flow from operations of $6.41B in 2025. The stock is near its consensus price target of $320.54, indicating potential upside.
Outlook is positive due to earnings momentum and portfolio simplification, but risks include integration challenges from spinoffs and macroeconomic sensitivity. Institutional sentiment is bullish with 66.7% buy ratings. Investors should monitor execution of growth strategies in building automation and aerospace segments for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
